Kazuki Hashimoto
Overview
Explore the profile of Kazuki Hashimoto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
172
Citations
1185
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sumitani H, Miki K, Yamamoto Y, Mihashi Y, Nagata Y, Miyamoto S, et al.
Respir Care
. 2025 Mar;
PMID: 40067680
Improving the anaerobic threshold (AT) provides benefits by avoiding overload, especially for patients with advanced COPD. However, the variables related to improving AT are poorly known. The aim of this...
2.
Hashimoto K, Abe Y, Fukushima K, Matsumoto Y, Saito H, Akamine Y, et al.
Emerg Infect Dis
. 2025 Mar;
31(3):624-627.
PMID: 40023820
We identified 2 novel species, Mycobacterium novusgordonae and M. shingordonae, from sputum specimens of pulmonary disease patients in Japan. Genetic and biochemical analyses revealed a close relationship with M. paragordonae....
3.
Hishida Y, Hashimoto K, Mochizuki R, Yasuda H, Nagasaka T, Deguchi Y, et al.
Eur J Endocrinol
. 2025 Feb;
192(3):K21-K25.
PMID: 39996308
Adrenal venous sampling (AVS) is an important procedure for determining primary aldosteronism (PA) subtypes. To guide the catheter to the adrenal veins and confirm cannulation, an iodinated contrast medium (ICM)...
4.
Kawamura Y, Shimomura A, Taniyama T, Hirai H, Hashimoto K, Honda Y, et al.
Case Rep Oncol
. 2025 Feb;
18(1):231-238.
PMID: 39980498
Introduction: Immune checkpoint inhibitors (ICIs), used in cancer immunotherapy, enhance the immune system's ability to attack cancer cells. However, this activation can lead to severe immune-associated adverse events due to...
5.
Tanzawa S, Yoshioka H, Misumi T, Miyauchi E, Ninomiya K, Murata Y, et al.
Ther Adv Med Oncol
. 2025 Feb;
17:17588359251318850.
PMID: 39957806
Background: The clinical impact of hypomagnesemia induced by necitumumab plus gemcitabine and cisplatin (GCN) as a second-line or later therapy is unclear. Objective: We aimed to evaluate the clinical characteristics...
6.
Sato K, Toh S, Murakami T, Nakano T, Hongo T, Matsuo M, et al.
Front Immunol
. 2025 Jan;
15:1464419.
PMID: 39867897
Background: Nivolumab paved a new way in the treatment of patients with recurrent or metastatic (RM) head and neck squamous cell carcinoma (RM-HNSCC). However, the limited rates of long-term survivors...
7.
Watanabe M, Takimoto H, Hashimoto K, Ishii Y, Sasaki N
Animal Model Exp Med
. 2025 Jan;
8(3):568-572.
PMID: 39843403
This study aimed to investigate the impact of administration routes in establishing the Adriamycin (ADR)-induced chronic kidney disease (CKD) model. Using BALB/c mice, we compared the effects of conventional tail-vein...
8.
Kawamura Y, Shimomura A, Taniyama T, Hirai H, Hashimoto K, Honda Y, et al.
Oncol Lett
. 2025 Jan;
29(3):136.
PMID: 39839606
Recently, the anti-programmed cell death protein 1 antibody pembrolizumab, a type of immune checkpoint inhibitor (ICI), has been used in preoperative systemic chemotherapy for hormone receptor and human epidermal growth...
9.
Dote M, Hamaguchi S, Arizono S, Cho S, Wada S, Nawata S, et al.
Radiol Case Rep
. 2025 Jan;
20(3):1574-1577.
PMID: 39816458
With advancements in medical devices and imaging techniques, endovascular treatment using stent grafts has emerged as a viable and aggressive therapeutic option for traumatic subclavian artery injuries, including iatrogenic cases....
10.
Shiga Y, Hashimoto K, Fujita K, Maekawa S, Sato K, Kubo S, et al.
Genet Med Open
. 2024 Dec;
2:100839.
PMID: 39669598
Purpose: Pathogenic variants in , , and are associated with primary open-angle glaucoma (POAG) with severe visual field defects. This study aims to understand further POAG-related pathogenic variant(s) based on...